NuCana PLC (NASDAQ:NCNA) has been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus target price of $26.50 for the company and are forecasting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also assigned NuCana an industry rank of 196 out of 265 based on the ratings given to related companies.
Several analysts have issued reports on NCNA shares. Jefferies Group started coverage on NuCana in a research note on Monday, October 23rd. They set a “buy” rating and a $25.00 price objective on the stock. Citigroup started coverage on NuCana in a research note on Monday, October 23rd. They set a “buy” rating and a $23.00 price objective on the stock. Zacks Investment Research upgraded NuCana from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Tuesday, December 26th. William Blair started coverage on NuCana in a research note on Monday, October 23rd. They set an “outperform” rating on the stock. Finally, Cowen started coverage on NuCana in a research note on Monday, October 23rd. They set an “outperform” rating on the stock.
Shares of NuCana (NASDAQ NCNA) traded down $1.69 during midday trading on Tuesday, reaching $24.96. The company’s stock had a trading volume of 109,039 shares, compared to its average volume of 211,822. NuCana has a 12-month low of $9.32 and a 12-month high of $29.75.
COPYRIGHT VIOLATION NOTICE: “Analysts Anticipate NuCana PLC (NCNA) to Post ($0.14) Earnings Per Share” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/30/analysts-anticipate-nucana-plc-ncna-to-post-0-14-earnings-per-share.html.
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.